|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.38 | 89.41 | 104.18 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
161.70
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | -0.23 | 1.43 | 17.14 | 13.62 | 9.39 | CEPS(Rs) | 5.36 | 6.18 | 21.36 | 17.63 | 12.93 | DPS(Rs) | 0.00 | 0.50 | 1.50 | 1.00 | 1.00 | Book NAV/Share(Rs) | 57.77 | 58.50 | 58.22 | 42.75 | 32.47 | Tax Rate(%) | 302.67 | 34.24 | 20.60 | 22.68 | 39.09 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 0.45 | 2.79 | 11.02 | 10.17 | 10.03 | EBIT Margin(%) | 1.63 | 2.10 | 9.90 | 9.24 | 8.74 | Pre Tax Margin(%) | 0.04 | 0.76 | 8.33 | 7.43 | 6.93 | PAT Margin (%) | -0.09 | 0.50 | 6.61 | 5.75 | 4.22 | Cash Profit Margin (%) | 2.06 | 2.15 | 8.24 | 7.44 | 5.82 | Performance Ratios | | | | | | ROA(%) | -0.10 | 0.73 | 10.73 | 9.58 | 7.45 | ROE(%) | -0.39 | 2.45 | 33.96 | 36.22 | 33.63 | ROCE(%) | 3.72 | 6.25 | 33.76 | 35.22 | 35.30 | Asset Turnover(x) | 1.10 | 1.47 | 1.62 | 1.67 | 1.76 | Sales/Fixed Asset(x) | 2.14 | 2.65 | 2.65 | 2.57 | 2.55 | Working Capital/Sales(x) | -40.94 | 43.31 | 17.44 | 36.96 | -41.80 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.47 | 0.38 | 0.38 | 0.39 | 0.39 | Receivable days | 126.69 | 94.48 | 83.54 | 81.82 | 81.06 | Inventory Days | 77.14 | 58.99 | 53.09 | 44.13 | 33.19 | Payable days | 261.92 | 180.39 | 188.38 | 200.40 | 191.20 | Valuation Parameters | | | | | | PER(x) | 0.00 | 121.57 | 13.41 | 6.97 | 17.35 | PCE(x) | 17.74 | 28.14 | 10.76 | 5.39 | 12.59 | Price/Book(x) | 1.65 | 2.97 | 3.95 | 2.22 | 5.01 | Yield(%) | 0.00 | 0.29 | 0.65 | 1.05 | 0.61 | EV/Net Sales(x) | 0.69 | 0.89 | 1.13 | 0.55 | 0.96 | EV/Core EBITDA(x) | 16.05 | 20.51 | 8.58 | 4.43 | 8.15 | EV/EBIT(x) | 37.17 | 36.59 | 9.99 | 5.25 | 9.63 | EV/CE(x) | 0.63 | 1.00 | 2.95 | 1.76 | 3.16 | M Cap / Sales | 0.42 | 0.70 | 1.01 | 0.45 | 0.84 | Growth Ratio | | | | | | Net Sales Growth(%) | -8.50 | 10.18 | 8.58 | 7.29 | 38.94 | Core EBITDA Growth(%) | -8.86 | -63.86 | 15.29 | 12.83 | 136.13 | EBIT Growth(%) | -29.79 | -76.41 | 17.14 | 12.78 | 204.33 | PAT Growth(%) | -115.93 | -91.66 | 25.86 | 45.12 | 338.09 | EPS Growth(%) | -115.93 | -91.66 | 25.86 | 45.12 | 338.09 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 1.10 | 0.83 | 0.49 | 0.52 | 0.82 | Current Ratio(x) | 0.96 | 1.05 | 1.15 | 1.07 | 0.94 | Quick Ratio(x) | 0.62 | 0.68 | 0.73 | 0.70 | 0.68 | Interest Cover(x) | 1.03 | 1.56 | 6.30 | 5.10 | 4.84 | Total Debt/Mcap(x) | 0.67 | 0.28 | 0.12 | 0.24 | 0.16 |
|
|
|
|
|
|